

**Electronic Supplementary Information for**


**Hyaluronic acid-mediated one-pot facile synthesis of a sensitive and biocompatible Gd<sub>2</sub>O<sub>3</sub> nanoprobe for MR Imaging in vivo**

Haoyu Wang,<sup>a</sup> Yan-Yan Fu,<sup>b</sup> Xuejun Zhang,<sup>b</sup> Chunshui Yu<sup>\*a,b</sup> and Shao-Kai Sun<sup>\*b</sup>


<sup>a</sup>Department of Radiology, Tianjin Key Laboratory of Functional Imaging, Tianjin

Medical University General Hospital, Tianjin 300052, China


<sup>b</sup>School of Medical Imaging, Tianjin Medical University, Tianjin 300203, China.




**Fig. S1.** The photographs of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobes prepared using different concentrations of Gd(NO<sub>3</sub>)<sub>3</sub> (0.02 M, 0.05 M, 0.1 M, 0.2 M, 0.5 M). The precipitation began to arise as the concentration of Gd<sup>3+</sup> increased to 0.2 M. So the 0.1 M was chosen to be the optimal reaction concentration to meet requirements in the aspects of high Gd content and good colloid stability.




**Fig. S2.** HRTEM of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobes




**Fig. S3.** The XRD of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe.



**Fig. S4.** The XPS patterns of Gd 4d for HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe.




**Fig. S5.** The measurements of dynamic light scattering (DLS) of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe dispersed in normal saline for 1 day and 30 days.




**Fig. S6.** The cell uptake of HA-Gd<sub>2</sub>O<sub>3</sub> after treatment with different mass of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe (25 µg, 125 µg). The following equations were used to evaluate the internalization of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe by cells.


$$\text{Percentage (\%)} = \text{Gd content in intracellular fluid} / \text{total Gd content} \times 100\%$$



**Fig. S7.** Time-dependent biodistribution measurement of Gd levels in various organs of mice after injection of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe at a dose of 0.025 mmol Gd/kg.



**Fig. S8.** Histology analysis of mice treated with and without intravenous injection of HA-Gd<sub>2</sub>O<sub>3</sub> nanoprobe (200  $\mu$ l, 0.025 mmol Gd /kg) at 1, 7 and 30 days.



**Fig. S9.** Average signal enhancement of major organs (kidney, adrenal gland, liver, spleen) after intravenous injection of HA-Gd<sub>2</sub>O<sub>3</sub> (200  $\mu$ l, 8 mg/mL)